Hero Background


Discover, design, and deliver the right drug for the right patient

Tempus provides integrated solutions to help meet your needs from early discovery through commercialization.


We partner with scientists and researchers to accelerate the drug development process

  • 90%

    of the top 20 pharma oncology companies partner with Tempus

  • 170+

    biopharma partnerships

image description

Our Differentiators

Data Collaborations

  • 6M+

    de-identified research records to power scientific discovery to improve patient outcomes

  • 700K+

    records with matched clinical data linked with genomic information to understand driver mutations and outcomes associations

  • 150K+

    records with full transcriptomic data for interrogating tumor biology and mechanisms of action

image description


  • 6

    NGS tests to support clinical trial and research sequencing

  • 5K+

    oncologists rely on Tempus as their precision medicine partner

image description

Clinical Trial Solutions

  • 10

    days on average to activate a new site

  • 200+

    provider networks and research institutions in the TIME Trial® Program

  • 20K+

    patients have been identified for potential enrollment into clinical trials in our network

image description
Our Impact

Thanks to Tempus, we are able to identify patients that can be helped with our proprietary TMod™ platform. Without them, we wouldn’t be able to do this.

William Go, SVP, Head of Development at A2 Biotherapeutics (TMod™ is a trademark of A2 Biotherapeutics)

Our Impact

Tempus is a leader in the field of personalized medicine, and like Genmab, Tempus has a mission to improve the lives of cancer patients. We are looking forward to expanding our exciting partnership with them and to the possibility of discovering important new oncology targets and biomarkers.

Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab

Learn more about our partnership with Genmab
Our Impact

Bayer’s strong focus in precision medicine combined with Tempus’ unique testing offering has culminated in this collaboration to bring genomic testing to cancer patients.

Bhavesh Ashar, Senior Vice President, Head of U.S. Oncology at Bayer

Learn more about our partnership with Bayer
Our Impact

Our partnership with Tempus will enable us to collect important retrospective information about the patients enrolled in the dose escalation part of our clinical trial that we can potentially use to inform enrollment in the expansion stage of our study.

Jorge DiMartino, Chief Medical Officer and Executive Vice President, Clinical Development at Kronos Bio

Learn more about our partnership with Kronos

Featured Resources


    Multimodal data drives biomarker innovation

    We spoke with Gilead experts to learn how the company uses multimodal data to achieve early successes in translational biomarker research and discovery.

    Read more

    The next evolution in drug development

    Hear from Janssen’s Dr. Najat Khan to find out how the company is applying advanced AI algorithms to RWD—with groundbreaking results.

    Read more

    Sequencing for development and commercialization

    Read about the experience of four organizations, who partnered with Tempus for prospective sequencing for clinical trials, retrospective sequencing and analyses, companion diagnostic development, and sponsored testing.

    Read more

    Enhanced biomarker discovery and design

    Combining sequencing, analytics, and data licensing with Tempus allows you to uncover new insights across R&D. Learn how one company made it happen.

    Read more

    Powering discovery: Tempus multimodal database

    Read about an example of how Tempus Multimodal Data enabled a pharmaceutical company to more quickly identify pancreatic cancer subtypes’ molecular signatures.

    Read more

    Patient recruitment at the speed of science

    Learn how Sermonix Pharmaceuticals partnered with Tempus and its TIME network of clinical sites to accelerate patient recruitment for a phase 2 study.

    Read more

    The promise of multimodal real-world data

    In this Q&A with Dr. Hisham Hamadeh of Genmab, we explore how using multimodal RWD can help organizations solve their toughest drug development challenges.

    Read more

Tempus empowers you to make smarter, faster, and more efficient decisions

Get customized solutions for your needs.